Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy
Authors:
- Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study groupCGCollaboration of Observational HIV Epidemiological Research Europe (COHERE) study group
- Julia BohliusJBJulia Bohlius
- Kurt SchmidlinKSKurt Schmidlin
- Dominique CostagliolaDCDominique Costagliola
- Gerd FätkenheuerGFGerd Fätkenheuer
- Margaret MayMMMargaret May
- Ana Maria Caro MurilloAMAna Maria Caro Murillo
- Amanda MocroftAMAmanda Mocroft
- Fabrice BonnetFBFabrice Bonnet
- Gary CliffordGCGary Clifford
- Giota TouloumiGTGiota Touloumi
- Jose M MiroJMJose M Miro
- 24 September 2009
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 23 (15) , 2029-2037
Abstract
We examined survival and prognostic factors of patients who developed HIV-associated non-Hodgkin lymphoma (NHL) in the era of combination antiretroviral therapy (cART). Multicohort collaboration of 33 European cohorts. We included all cART-naive patients enrolled in cohorts participating in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) who were aged 16 years or older, started cART at some point after 1 January 1998 and developed NHL after 1 January 1998. Patients had to have a CD4 cell count after 1 January 1998 and one at diagnosis of the NHL. Survival and prognostic factors were estimated using Weibull models, with random effects accounting for heterogeneity between cohorts. Of 67 659 patients who were followed up during 304 940 person-years, 1176 patients were diagnosed with NHL. Eight hundred and forty-seven patients (72%) from 22 cohorts met inclusion criteria. Survival at 1 year was 66% [95% confidence interval (CI) 63–70%] for systemic NHL (n = 763) and 54% (95% CI: 43–65%) for primary brain lymphoma (n = 84). Risk factors for death included low nadir CD4 cell counts and a history of injection drug use. Patients developing NHL on cART had an increased risk of death compared with patients who were cART naive at diagnosis. In the era of cART two-thirds of patients diagnosed with HIV-related systemic NHL survive for longer than 1 year after diagnosis. Survival is poorer in patients diagnosed with primary brain lymphoma. More advanced immunodeficiency is the dominant prognostic factor for mortality in patients with HIV-related NHL.Keywords
This publication has 30 references indexed in Scilit:
- Cancer risk in people infected with human immunodeficiency virus in the United StatesInternational Journal of Cancer, 2008
- A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral TherapyAnnals of Internal Medicine, 2005
- Survival After Cancer Diagnosis in Persons With AIDSJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral TherapyArchives of internal medicine (1960), 2005
- Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSInternational Journal of Epidemiology, 2004
- Malignancy‐related causes of death in human immunodeficiency virus–infected patients in the era of highly active antiretroviral therapyCancer, 2004
- Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected AdultsJNCI: Journal of the National Cancer Institute, 2000
- Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort studyBMJ, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre studyBMJ, 1997